Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Dow
McKinsey
Merck
AstraZeneca

Last Updated: October 13, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,114,394

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,114,394
Title:Use of IL-1 antagonists to treat gout
Abstract: Methods of treating, inhibiting, or ameliorating gout, including chronic acute (refractory) gout, pseudogout, or drug-induced gout, in a human subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the incidence of a gout flare is reduced or inhibited.
Inventor(s): Vicary; Catherine (New York, NY), Mellis; Scott (New Rochelle, NY)
Assignee: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)
Application Number:12/887,529
Patent Claims:1. A method of reducing the occurrence of gout flares in a subject, said method comprising administering to the subject a course of treatment comprising an interleukin-1 (IL-1) antagonist once per week, wherein the subject is treated concurrently with a uric acid synthesis inhibitor.

2. The method of claim 1, wherein the uric acid synthesis inhibitor is allopurinol.

3. The method of claim 1, wherein the IL-1 antagonist is an IL-1 trap.

4. The method of claim 3, wherein the IL-1 trap is rilonacept.

5. The method of claim 2, wherein the IL-1 antagonist is an IL-1 trap.

6. The method of claim 5, wherein the IL-1 trap is rilonacept.

7. The method of claim 1, wherein the IL-1 antagonist is administered at an initial dose of about 80 mg to about 500 mg on the first day of treatment.

8. The method of claim 7, wherein the IL-1 antagonist is an IL-1 trap.

9. The method of claim 8, wherein the IL-1 trap is rilonacept.

10. The method of claim 9, wherein the rilonacept is administered at an initial dose of 320 mg on the first day of treatment.

11. The method of claim 7, wherein the IL-1 antagonist is administered at subsequent doses of about 40 mg to about 250 mg.

12. The method of claim 11, wherein the IL-1 antagonist is an IL-1 trap.

13. The method of claim 12, wherein the IL-1 trap is rilonacept.

14. The method of claim 13, wherein the rilonacept is administered at subsequent doses of 160 mg.

15. The method of claim 11, wherein the uric acid synthesis inhibitor is allopurinol.

16. The method of claim 12, wherein the uric acid synthesis inhibitor is allopurinol.

17. The method of claim 13, wherein the uric acid synthesis inhibitor is allopurinol.

18. The method of claim 14, wherein the uric acid synthesis inhibitor is allopurinol.

19. The method of claim 1, wherein the course of treatment is administered for 16 weeks.

20. The method of claim 1, wherein the IL-1 antagonist is administered subcutaneously.

Details for Patent 8,114,394

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Regeneron Pharmaceuticals ARCALYST rilonacept VIAL; SINGLE-USE 125249 001 2008-02-27   See Pricing Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2026-10-20 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 8,114,394

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Baxter
Johnson and Johnson
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.